

Lorenzo Giovanni Mantovani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9032377/publications.pdf>

Version: 2024-02-01

196
papers

8,121
citations

50170

46
h-index

56606

83
g-index

200
all docs

200
docs citations

200
times ranked

9969
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 178.	1.1	8
2	Editorial to Chuang et al. <i>IJC Heart and Vasculature</i> , 2022, 39, 100963.	0.6	0
3	Haemophilia management and treatment: An Italian survey on patientsâ€™, caregiversâ€™ and cliniciansâ€™ point of view. <i>Haemophilia</i> , 2022, 28, 254-263.	1.0	5
4	Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. <i>PLoS ONE</i> , 2022, 17, e0264123.	1.1	2
5	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. <i>International Journal of Cardiology</i> , 2022, 356, 12-18.	0.8	6
6	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	0.9	10
7	Cost-effectiveness of the early arthritis clinic organizational model: the <sc>ELECTRA</sc> study. <i>Arthritis Care and Research</i> , 2022, , .	1.5	1
8	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. <i>Value in Health</i> , 2022, 25, 1489-1498.	0.1	2
9	Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women. <i>Atherosclerosis</i> , 2021, 317, 59-66.	0.4	6
10	COVID-19 and Obesity: Is Bariatric Surgery Protective? Retrospective Analysis on 2145 Patients Undergone Bariatric-Metabolic Surgery from High Volume Center in Italy (Lombardy). <i>Obesity Surgery</i> , 2021, 31, 942-948.	1.1	16
11	Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). <i>Thrombosis and Haemostasis</i> , 2021, 121, 206-215.	1.8	12
12	Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990â€“2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 385-396.	0.8	34
13	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
14	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELDâ€VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	1.0	23
15	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIAâ€LEA noninterventional studies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 426-438.	1.0	10
16	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 459-468.	1.1	5
17	Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. <i>Haemophilia</i> , 2021, 27, e422-e433.	1.0	14
18	COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1115-1118.	1.8	3

#	ARTICLE	IF	CITATIONS
19	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies. PLoS ONE, 2021, 16, e0254631.	1.1	7
20	Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing <sc>ICD</sc> explant procedures: Clinical and economic implications. Clinical Cardiology, 2021, 44, 1497-1505.	0.7	7
21	Efficiency measures of emergency departments: an Italian systematic literature review. BMJ Open Quality, 2021, 10, e001058.	0.4	22
22	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism â€” The COSIMO study. Thrombosis Research, 2021, 206, 1-4.	0.8	10
23	Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. ESC Heart Failure, 2021, 8, 1139-1149.	1.4	18
24	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. Journal of Thrombosis and Haemostasis, 2021, , .	1.9	8
25	Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A. Journal of Blood Medicine, 2021, Volume 12, 935-943.	0.7	3
26	Cancer-Associated Thromboses â€” Patient-Reported Outcomes With Rivaroxaban (COSIMO) â€” Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12604.	1.0	3
27	Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 13253.	1.2	8
28	Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology. Liver International, 2020, 40, 60-73.	1.9	5
29	Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thrombosis and Haemostasis, 2020, 120, 216-228.	1.8	48
30	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. International Journal of Stroke, 2020, 15, 308-317.	2.9	12
31	Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 1425-1436.	1.2	88
32	Estimates of Cancer Mortality Attributable to Carcinogenic Infections in Italy. International Journal of Environmental Research and Public Health, 2020, 17, 8723.	1.2	5
33	Severe Acute Respiratory Syndrome Coronavirus 2 Lethality Did not Change Over Time in Two Italian Provinces. Open Forum Infectious Diseases, 2020, 7, ofaa556.	0.4	8
34	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Network Open, 2020, 3, e2022886.	2.8	28
35	Health related quality of life in chronic liver diseases. Liver International, 2020, 40, 2630-2642.	1.9	15
36	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy. ERJ Open Research, 2020, 6, 00179-2020.	1.1	12
38	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart, 2020, 106, 1519-1524.	1.2	83
39	A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. International Journal of Cardiology, 2020, 319, 85-93.	0.8	4
40	Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. PLoS ONE, 2020, 15, e0235248.	1.1	71
41	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis, 2020, 50, 267-277.	1.0	54
42	SARS-CoV-2 pandemic: An overview. Advances in Biological Regulation, 2020, 77, 100736.	1.4	65
43	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research, 2020, 191, 103-112.	0.8	22
44	Title is missing!. , 2020, 15, e0235248.		0
45	Title is missing!. , 2020, 15, e0235248.		0
46	Title is missing!. , 2020, 15, e0235248.		0
47	Title is missing!. , 2020, 15, e0235248.		0
48	Title is missing!. , 2020, 15, e0235248.		0
49	Title is missing!. , 2020, 15, e0235248.		0
50	Title is missing!. , 2020, 15, e0235248.		0
51	Title is missing!. , 2020, 15, e0235248.		0
52	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1675-1685.	1.8	34
53	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. TH Open, 2019, 03, e85-e93.	0.7	20
54	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. Journal of Thrombosis and Haemostasis, 2019, 17, 1694-1706.	1.9	30

#	ARTICLE	IF	CITATIONS
55	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
56	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
57	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 497-509.	1.0	24
58	Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1562861.	0.8	11
59	Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1126-1133.	1.9	13
60	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019, 176, 125-132.	0.8	17
61	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
62	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
63	Leadership in Public Health: Opportunities for Young Generations Within Scientific Associations and the Experience of the "Academy of Young Leaders". <i>Frontiers in Public Health</i> , 2019, 7, 378.	1.3	33
64	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
65	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. <i>European Journal of Internal Medicine</i> , 2019, 61, 29-33.	1.0	3
66	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
67	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. <i>Drug Safety</i> , 2019, 42, 347-363.	1.4	65
68	Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. <i>Blood</i> , 2019, 134, 2159-2159.	0.6	14
69	Moving Towards Accountability for Reasonableness " A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study. <i>International Journal of Health Policy and Management</i> , 2019, 8, 424-443.	0.5	10
70	Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2018, 36, 567-589.	1.7	39
71	Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. <i>Pharmacoeconomics</i> , 2018, 36, 263-284.	1.7	13
72	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	1.8	3

#	ARTICLE	IF	CITATIONS
73	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. <i>TH Open</i> , 2018, 02, e139-e146.	0.7	5
74	Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	0.8	15
75	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
76	COSIMO â€“ patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.	0.9	20
77	Peripheral arterial disease in diabetic patients: a long-term population-based study on occurrence, outcomes and cost. <i>Journal of Cardiovascular Surgery</i> , 2018, 59, 572-579.	0.3	4
78	Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 68.	1.0	16
79	Predictive value of venous thromboembolism (<sc>VTE</sc>)â€™<sc>BLEED</sc> to predict major bleeding and other adverse events in a practiceâ€™based cohort of patients with <sc>VTE</sc>: results of the <sc>XALIA</sc> study. <i>British Journal of Haematology</i> , 2018, 183, 457-465.	1.2	32
80	Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 749-757.	0.7	11
81	The socioeconomic burden of patients affected by hemophilia with inhibitors. <i>European Journal of Haematology</i> , 2018, 101, 435-456.	1.1	37
82	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
83	Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery. <i>Spine</i> , 2017, 42, 1398-1404.	1.0	27
84	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. <i>Thrombosis Research</i> , 2017, 155, 23-27.	0.8	9
85	Directâ€™acting antivirals combination for elderly patients with chronic hepatitis C: A costâ€™effectiveness analysis. <i>Liver International</i> , 2017, 37, 982-994.	1.9	19
86	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. <i>TH Open</i> , 2017, 01, e33-e42.	0.7	18
87	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. <i>European Journal of Heart Failure</i> , 2017, 19, 1551-1553.	2.9	10
88	Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 425-430.	0.5	21
89	Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 627-637.	0.5	20
90	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92

#	ARTICLE	IF	CITATIONS
91	Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. <i>Blood Advances</i> , 2017, 1, 2637-2642.	2.5	9
92	Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. <i>Obesity Facts</i> , 2017, 10, 261-272.	1.6	20
93	Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. <i>PLoS ONE</i> , 2017, 12, e0179523.	1.1	6
94	Letter to the editor: Clinical Use, Quality of Life and Cost-Effectiveness of Spinal Cord Stimulation Used to Treat Patients with Failed Back Surgery Syndrome. <i>Asian Spine Journal</i> , 2017, 11, 675-676.	0.8	1
95	The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. <i>Vascular Health and Risk Management</i> , 2016, 12, 209.	1.0	9
96	Global Anticoagulant Registry in the Field " Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	1.8	46
97	Regarding "Exploring patient involvement in decision making for vascular procedures". <i>Journal of Vascular Surgery</i> , 2016, 63, 1668.	0.6	0
98	Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 724-734.	1.1	17
99	Drug utilization research and pharmacoeconomics. , 2016, , 425-432.		0
100	Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. <i>Hepatology</i> , 2016, 64, 1331-1342.	3.6	10
101	Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The <sc>ITER</sc> Study). <i>Haemophilia</i> , 2016, 22, 96-102.	1.0	37
102	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. <i>Dermatology and Therapy</i> , 2016, 6, 151-167.	1.4	10
103	Real life studies and good clinical practice " Authors' reply. <i>Lancet Haematology</i> ,the, 2016, 3, e160-e161.	2.2	1
104	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. <i>Lancet Haematology</i> ,the, 2016, 3, e12-e21.	2.2	215
105	Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 138-146.	0.7	18
106	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
107	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. <i>Blood</i> , 2016, 128, 1438-1438.	0.6	2
108	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118

#	ARTICLE	IF	CITATIONS
109	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 68-75.	0.4	7
110	Cost-effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values. <i>Hepatology</i> , 2015, 61, 1096-1097.	3.6	2
111	The societal burden of chronic liver diseases: results from the COME study. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000025.	1.1	38
112	Health economic models in hemophilia A and utility assumptions from a clinician's perspective. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1826-1831.	0.8	19
113	Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study. <i>Neuromodulation</i> , 2015, 18, 266-276.	0.4	77
114	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74
115	Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. <i>American Journal of Transplantation</i> , 2015, 15, 1817-1826.	2.6	19
116	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015, 17, 1007-1017.	0.7	46
117	Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. <i>British Journal of Dermatology</i> , 2015, 172, 187-195.	1.4	15
118	Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. <i>Journal of Viral Hepatitis</i> , 2015, 22, 175-183.	1.0	19
119	Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?. <i>Blood</i> , 2015, 126, 289-289.	0.6	3
120	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 894-894.	0.6	2
121	KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting. <i>PLoS ONE</i> , 2014, 9, e85897.	1.1	12
122	The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. <i>PLoS ONE</i> , 2014, 9, e101228.	1.1	79
123	Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. <i>Contact Dermatitis</i> , 2014, 70, 158-168.	0.8	34
124	The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 21.	2.5	4
125	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 16.	0.9	27
126	A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 94-102.	1.8	74

#	ARTICLE	IF	CITATIONS
127	Burden of Diabetes Mellitus Estimated with a Longitudinal Population-Based Study Using Administrative Databases. PLoS ONE, 2014, 9, e113741.	1.1	24
128	The social burden and quality of life of patients with haemophilia in Italy. Blood Transfusion, 2014, 12 Suppl 3, s567-75.	0.3	22
129	Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 2013, 22, 1707-1716.	1.5	108
130	Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry, 2013, 13, 98.	1.1	19
131	Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the ProFEIBA study. Haemophilia, 2013, 19, 736-743.	1.0	59
132	Italian Population-Based Values of EQ-5D Health States. Value in Health, 2013, 16, 814-822.	0.1	122
133	Patient preferences and willingness to pay for different options of anticoagulant therapy. Internal and Emergency Medicine, 2013, 8, 237-243.	1.0	31
134	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. European Heart Journal, 2013, 34, 1869-1874.	1.0	85
135	The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. BMJ Open, 2013, 3, e001309.	0.8	3
136	Healthcare costs associated with hepatocellular carcinoma and the value of care. Hepatology, 2013, 58, 1213-1214.	3.6	7
137	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 2013, 8, e63479.	1.1	375
138	Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis. PLoS ONE, 2013, 8, e75047.	1.1	11
139	Pharmacoeconomic Issues in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 103-105.	2.2	10
140	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal, 2012, 163, 13-19.e1.	1.2	195
141	Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infectious Diseases, 2012, 12, 207.	1.3	121
142	The Economic Impact of Long-Term Oxygen Therapy. , 2012, , 221-232.		0
143	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management, 2012, 8, 363.	1.0	17
144	The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People. Drug Safety, 2012, 35, 73-87.	1.4	113

#	ARTICLE	IF	CITATIONS
145	Haemophilia prophylaxis: how can we justify the costs?. Haemophilia, 2012, 18, 680-684.	1.0	17
146	Haemophilia Care in Europe: the ESCHQoL study. Haemophilia, 2012, 18, 729-737.	1.0	45
147	Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies. Blood, 2012, 120, 500-500.	0.6	2
148	Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy.. Journal of Clinical Oncology, 2012, 30, e14113-e14113.	0.8	0
149	Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2012, 30, S72-84.	0.4	55
150	Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clinical and Experimental Rheumatology, 2012, 30, S126-31.	0.4	20
151	The rationale of pharmacoeconomic analysis in rheumatologic indications. Clinical and Experimental Rheumatology, 2012, 30, S64-71.	0.4	11
152	Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. New England Journal of Medicine, 2011, 365, 1684-1692.	13.9	209
153	Burden of acute myocardial infarction. International Journal of Cardiology, 2011, 150, 111-112.	0.8	20
154	The economic burden of chronic obstructive pulmonary disease in the elderly. Current Opinion in Pulmonary Medicine, 2011, 17, S35-S41.	1.2	30
155	Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia, 2011, 17, 383-392.	1.0	52
156	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). Journal of Thrombosis and Haemostasis, 2011, 9, 700-710.	1.9	390
157	Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace, 2011, 13, ii59-ii65.	0.7	50
158	Cardiac resynchronization therapy: a cost or an investment?. Europace, 2011, 13, ii32-ii38.	0.7	19
159	Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace, 2011, 13, ii49-ii53.	0.7	22
160	Economic evaluation in cardiology. Europace, 2011, 13, ii3-ii8.	0.7	26
161	Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA. Clinical and Experimental Hypertension, 2011, 33, 174-178.	0.5	4
162	A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thrombosis and Haemostasis, 2010, 103, 968-975.	1.8	46

#	ARTICLE	IF	CITATIONS
163	Cost-benefit analysis of supplemented very low-protein diet versus dialysis in elderly CKD5 patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 907-913.	0.4	41
164	Amlodipine: a pharmacoeconomic review. <i>Journal of Medical Economics</i> , 2009, 12, 60-68.	1.0	11
165	Setting dialysis start at 6.0 ml/min/1.73 m ² eGFR—a study on safety, quality of life and economic impact. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3434-3440.	0.4	26
166	Psoriatic arthritis: Pharmacoeconomic considerations. <i>Current Rheumatology Reports</i> , 2009, 11, 263-269.	2.1	8
167	Patients'™, physicians'™, and pharmacists'™ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. <i>Haemophilia</i> , 2009, 15, 473-486.	1.0	27
168	Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. <i>Haemophilia</i> , 2009, 15, 639-658.	1.0	143
169	Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients. <i>Circulation</i> , 2009, 120, 1598-1605.	1.6	524
170	Oral antiviral therapies are cost-effective vs. no treatment but indirect comparisons should be avoided. <i>Journal of Hepatology</i> , 2009, 51, 1086-1087.	1.8	1
171	An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. <i>Value in Health</i> , 2008, 11, 791-799.	0.1	51
172	European principles of haemophilia care. <i>Haemophilia</i> , 2008, 14, 361-374.	1.0	191
173	Detection and Awareness of Moderate to Advanced CKD by Primary Care Practitioners: A Cross-sectional Study From Italy. <i>American Journal of Kidney Diseases</i> , 2008, 52, 444-453.	2.1	98
174	The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 46-51.	2.2	5
175	Costs, quality of life, treatment satisfaction and compliance in patients with β^2 -thalassemia major undergoing iron chelation therapy: the ITHACA study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1905-1917.	0.9	101
176	Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. <i>Vaccine</i> , 2008, 26, F16-F28.	1.7	37
177	Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2007, 13, 38-45.	1.0	47
178	Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. <i>Haemophilia</i> , 2007, 13, 473-479.	1.0	68
179	Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. <i>Haemophilia</i> , 2007, 14, 071115150757005-???	1.0	24
180	Cost-effectiveness of different diagnostic strategies to assess gastro-oesophageal reflux disease in patients with unexplained chronic persistent cough in Italy. <i>Digestive and Liver Disease</i> , 2006, 38, 452-458.	0.4	9

#	ARTICLE	IF	CITATIONS
181	Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA. <i>Pharmacological Research</i> , 2006, 53, 197-201.	3.1	7
182	The pharmacoeconomic impact of amlodipine use on coronary artery disease. <i>Pharmacological Research</i> , 2006, 54, 158-163.	3.1	17
183	Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. <i>Haemophilia</i> , 2006, 12, 154-162.	1.0	146
184	Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2006, 12, 363-371.	1.0	94
185	Major complications have an impact on total annual medical cost of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 163-169.	1.2	55
186	Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. <i>Journal of Hypertension</i> , 2005, 23, 2093-2100.	0.3	163
187	Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. <i>Haemophilia</i> , 2005, 11, 353-359.	1.0	24
188	Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. <i>Haemophilia</i> , 2005, 11, 589-597.	1.0	60
189	Reply to the Letter to the Editor by Hughes in response to the article entitled "Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced NSCLC", published in vol. 41 Issue 1 of the <i>European Journal of Cancer</i> . <i>European Journal of Cancer</i> , 2005, 41, 1656-1657.	1.3	1
190	Major Diabetes Complications Have an Impact on Total Annual Medical Cost of Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1841-1842.	4.3	11
191	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. <i>Blood</i> , 2003, 102, 2358-2363.	0.6	351
192	Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic Studies. <i>Drug Information Journal</i> , 2001, 35, 189-201.	0.5	84
193	CAPTOPRIL IN THE MANAGEMENT OF PATIENTS AFTER ACUTE MYOCARDIAL INFARCTIONS. A COST EFFECTIVENESS ANALYSIS IN ITALY. <i>Pharmacological Research</i> , 1998, 37, 345-351.	3.1	7
194	THE PERSPECTIVE OF A PHARMACOECONOMIC STUDY: TARGETING FOR AUDIENCES. <i>Pharmacological Research</i> , 1997, 35, 471-475.	3.1	6
195	Is Preventive Medical Care Worth the Cost?. <i>Biologicals</i> , 1997, 25, 247-252.	0.5	0
196	A Proposal For Italian Guidelines in Pharmacoeconomics. <i>Pharmacoeconomics</i> , 1995, 7, 1-6.	1.7	71